cas 39830-66-5|| where to buy methyl 1H-indole-4-carboxylate

Nombre del producto:methyl 1H-indole-4-carboxylate

IUPAC Name:methyl 1H-indole-4-carboxylate

Unidad de embalaje	Stock disponible	Precio($)
CM103240-25g	in stock	ȌƋƼ
CM103240-100g	in stock	ɐƼǲ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 39830-66-5 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :39830-66-5; Fórmula molecular:C10H9NO2; Punto de fusión:-; Código de sonrisas:C1=C[NH]C2=C1C(=CC=C2)C(OC)=O; Densidad:

: Número de catálogo:CM103240; Peso molecular:175.19; Punto de ebullición:331.7°C at 760 mmHg; Nº Mdl:MFCD00191222; Almacenamiento:Store at room temperature.

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.; indole company; As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

: Bexicaserin; Longboard announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The analysis showed that bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures across the DEE study population. Longboard will rapidly advance bexicaserin's global Phase 3 trial.